Business Description
Prelude Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US74065P1012
Share Class Description:
PRLD: Ordinary SharesTotal Employee Number:
79Description
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.6 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | -0.22 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -5.83 | |||||
Beneish M-Score | -3 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 19.7 | |||||
3-Year EPS without NRI Growth Rate | 19.1 | |||||
3-Year FCF Growth Rate | 26.3 | |||||
3-Year Book Growth Rate | -35.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 29.53 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 111.33 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.94 | |||||
9-Day RSI | 42.02 | |||||
14-Day RSI | 47.13 | |||||
3-1 Month Momentum % | 2.75 | |||||
6-1 Month Momentum % | 100.45 | |||||
12-1 Month Momentum % | 451.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.03 | |||||
Quick Ratio | 2.03 | |||||
Cash Ratio | 1.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.5 | |||||
Shareholder Yield % | 0.07 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -503.21 | |||||
Net Margin % | -465.3 | |||||
EBITDA Margin % | -493.24 | |||||
FCF Margin % | -261.82 | |||||
OCF Margin % | -261.7 | |||||
ROE % | -106.17 | |||||
ROA % | -63.57 | |||||
ROIC % | -143.79 | |||||
3-Year ROIIC % | 33.85 | |||||
ROC (Joel Greenblatt) % | -254.27 | |||||
ROCE % | -91.79 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 20.93 | |||||
PB Ratio | 4.63 | |||||
Price-to-Tangible-Book | 4.62 | |||||
EV-to-EBIT | -3.44 | |||||
EV-to-Forward-EBIT | -2.31 | |||||
EV-to-EBITDA | -3.51 | |||||
EV-to-Revenue | 17.33 | |||||
EV-to-FCF | -6.62 | |||||
| Price-to-Net-Current-Asset-Value | 11.09 | |||||
| Price-to-Net-Cash | 12.67 | |||||
Earnings Yield (Greenblatt) % | -29.07 | |||||
FCF Yield % | -12.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PRLD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Prelude Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 16.72 | ||
| EPS (TTM) ($) | -1 | ||
| Beta | 2.1328 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 1.07 | ||
| Volatility % | 115.61 | ||
| 14-Day RSI | 47.13 | ||
| 14-Day ATR ($) | 0.435775 | ||
| 20-Day SMA ($) | 4.629 | ||
| 12-1 Month Momentum % | 451.12 | ||
| 52-Week Range ($) | 0.75 - 5.69 | ||
| Shares Outstanding (Mil) | 79.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Prelude Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Prelude Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 31 days | ||
| Goldman Sachs 47 Annual Global Healthcare Conference | 2026-06-10 11:20 | 3.94 (+1.81%) | ||
| General meeting for 2026 | 2026-06-09 08:30 | 3.84 (-0.52%) | ||
| Guidance call for 2026 | 2026-06-03 12:15 | 3.50 (-6.91%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 4.80 (-1.03%) | ||
| The Citizens Life Sciences Conference | 2026-03-10 15:25 | 3.09 (-3.13%) | ||
| Annual report for 2025 | 2026-03-10 | 3.09 (-3.13%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 3.09 (-3.13%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 1.35 (+6.30%) |
Show
Entries
Prelude Therapeutics Inc Frequently Asked Questions
What is Prelude Therapeutics Inc(PRLD)'s stock price today?
The current price of PRLD is $4.43. The 52 week high of PRLD is $5.69 and 52 week low is $0.75.
When is next earnings date of Prelude Therapeutics Inc(PRLD)?
The next earnings date of Prelude Therapeutics Inc(PRLD) is 2026-08-14 Est..
Does Prelude Therapeutics Inc(PRLD) pay dividends? If so, how much?
Prelude Therapeutics Inc(PRLD) does not pay dividend.
Guru Commentaries on NAS:PRLD
No articles.
Press Release
Articles on Prelude Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers